Back ground: Non-Hodgkin’s lymphoma (NHL)
with its different subtypes is strongly related to Epstein Bar virus (EBV)
infection mainly Burkitt’s lymphoma in Africa. Studies proved the role of EBV
in tumor-genesis and linked it to prognosis and therapy of patients.
Objectives: To determine the frequency of EBV in non-Hodgkin lymphomas using
EBV latent membrane protein 1 (EBV-LMP1) immunohistochemical stain. Methods:
This cross-sectional study was conducted at radio-isotope centre of Khartoum
(2012-2014). A total of 75 cases of non-Hodgkin lymphoma paraffin embedded
sections were stained for EBV LMP1 antibody. Data were analyzed by SPSS 16 and
statistical cross linking of the results of immune staining with other data was
done. Results: Out of 75 patients of non Hodgkin’s lymphoma (74.7%) were males.
EBV-LMP1 Immune-staining was positive in (17.3%) with predominance of Burkitt’s
lymphoma (33.3%), followed by diffuse large B cell lymphoma (17.9%).
Conclusion: Burkitt’s lymphoma expressed the highest percentage of
non-Hodgkin’s lymphoma positive cases (46.2%) out of the total (17.3%) positive
cases. Different methods need to be used in studying Burkitt’s lymphoma
expression of EBV and its effects on the treatment and prognosis of cases.
References
[1]
Crawford, D.H. (2001) Biology and Disease Associations of Epstein-Barr Virus. Philosophical Transactions of the Royal Society B: Biological Science, 356, 461-473. http://dx.doi.org/10.1098/rstb.2000.0783
[2]
Kieff, E. and Rickinson, A.B. (2001) In: Knipe, D.M., Howley, P.M. and Griffin, D.E., Eds., Fields Virology, Lippincott Williams & Wilkins, Philadelphia, 2511-2573.
[3]
Wilson, J.B., Weinberg, W., Johnson, R., Yuspa, S. and Levine, A.J. (1990) Expression of the BNLF-1 Oncogene of Epstein-Barr Virus in the Skin of Transgenic Miceinduces Hyperplasia and Aberrant Expression of Keratin 6. Cell, 61, 1315-1327. http://dx.doi.org/10.1016/0092-8674(90)90695-B
[4]
Kulwichit, W., Edwards, R.H., Davenport, E.M., Baskar, J.F., Godfrey, V. and Raab-Traub, N. (1998) Expression of the Epstein-Barr Virus Latent Membrane Protein 1 Induces B Cell Lymphoma in Transgenic Mice. Proceedings of the National Academy of Sciences of the United States of America, 95, 11963-11968. http://dx.doi.org/10.1073/pnas.95.20.11963
[5]
Stevenson, D., Charalambous, C. and Wilson, J.B. (2005) Epstein-Barr Virus Latent Membrane Protein 1 (CAO) Up-Regulates VEGF and TGFa Concomitant with Hyperlasia, with Subsequent Up-Regulation of p16 and MMP9. Cancer Research, 65, 8826-8835. http://dx.doi.org/10.1158/0008-5472.CAN-05-0591
[6]
Young, L.S. and Murray, P.G. (2003) Epstein-Barr Virus and Oncogenesis: From Latent Genes to Tumours. Oncogene, 22, 5108-5121. http://dx.doi.org/10.1038/sj.onc.1206556
[7]
Shair, K.H., Bendt, K.M., Edwards, R.H., Bedford, E.C., Nielsen, J.N. and Raab-Traub, N. (2007) EBV Latent Membrane Protein 1 Activates Akt, NFkappaB, and Stat3 in B cell Lymphomas. PLOS Pathogens, 3, e166. http://dx.doi.org/10.1371/journal.ppat.0030166
[8]
Ferlay, J., Shin, H.R. and Bray, F. (2008) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. http://dx.doi.org/10.1002/ijc.25516
[9]
Gaidano, G., Pastore, C. and Volpe, G. (1995) Molecular Pathogenesis of Non-Hodgkin Lymphoma: A Clinical Perspective. Haematologica, 80, 454-472.
[10]
Grulich, A.E., Vajdic, C.M. and Cozen, W. (2007) Altered Immunity as a Risk Factor for Non-Hodgkin Lymphoma. Cancer Epidemiology, Biomarkers & Prevention, 16, 405-408.
[11]
Vrzalikova, K., Vockerodt, M., Leonard, S., Bell, A., Wei, W., Schrader, A., Wright, K.L., Kube, D., Rowe, M., Woodman, C.B. and Murray, P.G. (2011) Down-Regulation of BLIMP1α by the EBV Oncogene, LMP-1, Disrupts the Plasma Cell Differentiation Program and Prevents Viral Replication in B Cells: Implications for the Pathogenesis of EBV-Associated B-Cell Lymphomas. Blood, 117, 5907-5917. http://dx.doi.org/10.1182/blood-2010-09-307710
[12]
Mei, Y.P., Zhou, J.M., Wang, Y., Huang, H., et al. (2007) Silencing of LMP1 Induces Cell Cycle Arrest and Enhances Chemosensitivity through Inhibition of AKT Signaling Pathway in EBV Positive Nasopharyngeal Carcinoma Cells. Cell Cycle, 6, 1379-1385. http://dx.doi.org/10.4161/cc.6.11.4274
[13]
Khabir, A., Karray, H., Rodriguez, S., Rosé, M., Daoud, J., Frikha, M., Boudawara, T., Middeldorp, J., Jlidi, R. and Busson, P. (2005) EBV Latent Membrane Protein 1 Abundance Correlates with Patient Age but Not with Metastatic Behavior in North African Nasopharyngeal Carcinomas. Virology Journal, 2, 39. http://dx.doi.org/10.1186/1743-422X-2-39
[14]
Nourse, J.P., Crooks, P., Keane, C., Nguyen-Van, D., Mujaj, S., Ross, N., Jones, K., Vari, F., Han, E., Trappe, R., Fink, S. and Gandhi, M.K. (2012) Expression Profiling of Epstein-Barr Virus-Encoded microRNAs from Paraffin-Embedded Formalin-Fixed Primary Epstein-Barr Virus-Positive B-Cell Lymphoma Samples. Journal of Virological Methods, 184, 46-54. http://dx.doi.org/10.1016/j.jviromet.2012.05.005
[15]
Omoti, C.E., Nwannadi, A.I., Obieche, J.C. and Olu-Eddo, A.N. (2012) The Epidemiological Features of Lymphoid Malignancies in Benin City, Nigeria: A 15 Years Study. The Pan African Medical Journal, 11, 10.
[16]
Ishtiaq, S., Hassan, U., Mushtaq, S. and Akhtar, N. (2013) Determination of Frequency of Epstein-Barr Virus in Non-Hodgkin Lymphomas Using EBV Latent Membrane Protein 1 (EBV-LMP1) Immunohistochemical Staining. Asian Pacific Journal of Cancer Prevention, 14, 3963-3967. http://dx.doi.org/10.7314/APJCP.2013.14.6.3963
[17]
Gonin, J., Larousserie, F., Bastard, C., Picquenot, J.-M., Couturier, J., Radford-Weiss, I., Dietrich, C., et al. (2011) Epstein-Barr Virus-Induced Gene 3 (EBI3): A Novel Diagnosis Marker in Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma. PLoS ONE, 6, e24617. http://dx.doi.org/10.1371/journal.pone.0024617
[18]
Oyama, T., Yamamoto, K., Asano, N., Oshiro, A., Suzuki, R., Kagami, Y., Morishima, Y., Takeuchi, K., Izumo, T., Mori, S., Ohshima, K., Suzumiya, J., Nakamura, N., et al. (2007) Age-Related EBV Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients. Clinical Cancer Research, 13, 5124-5132. http://dx.doi.org/10.1158/1078-0432.CCR-06-2823
[19]
Morales, D., Beltran, B., De Mendoza, F.H., Riva, L., Yabar, A., Quinones, P., Butera, J.N. and Castillo, J. (2010) Epstein-Barr Virus as a Prognostic Factor in de Novo Nodal Diffuse Large B-Cell Lymphoma. Leukemia & Lymphoma, 51, 66-72. http://dx.doi.org/10.3109/10428190903308015
[20]
Park, S., Lee, J., Ko, Y.H., Han, A., Jun, H.J., Lee, S.C., Hwang, I.G., Park, Y.H., Ahn, J.S., Jung, C.W., Kim, K., Ahn, Y.C., Kang, W.K., Park, K. and Kim, W.S. (2007) The Impact of Epstein-Barr Virus Status on Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood, 110, 972-978. http://dx.doi.org/10.1182/blood-2007-01-067769
[21]
Adam, P., Bonzheim, I., Fend, F. and Quintanilla-Martínez, L. (2011) Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphomas of the Elderly. Advances in Anatomic Pathology, 18, 349-355. http://dx.doi.org/10.1097/PAP.0b013e318229bf08
[22]
Tumwine, L.K., Orem, J., Kerchan, P., Byarugaba, W. and Pileri, S.A. (2010) EBV, HHV8 and HIV in B Cell Non Hodgkin Lymphoma in Kampala, Uganda. Infectious Agents and Cancer, 5, 12. http://dx.doi.org/10.1186/1750-9378-5-12
[23]
Osman, I.M., Mohamadani, A. and Mohamed Kheir, S. (2014) Non-Hodgkin Lymphoma in Sudanese Children. Sudan Journal of Medical Sciences, 9, 31-38.
[24]
Mao, Y., Zhang, D.-W., Zhu, H., Lin, H., Xiong, L., Cao, Q., Liu, Y., Li, Q.-D., Xu, J.-R., Xu, L.-F. and Chen, R.-J. (2012) LMP1 and LMP2A Are Potential Prognostic Markers of Extranodal NK/T-Cell Lymphoma, Nasal Type (ENKTL). Diagnostic Pathology, 7, 178. http://dx.doi.org/10.1186/1746-1596-7-178
[25]
Horikawa, T., Yoshizaki, T., Sheen, T.-S., Lee, S.-Y. and Furukawa, M. (2000) Association of Latent Membrane Protein 1 and Matrix Metalloproteinase 9 with Metastasis in Nasopharyngeal Carcinoma. Cancer, 89, 715-723. http://dx.doi.org/10.1002/1097-0142(20000815)89:4<715::aid-cncr1>3.0.co;2-9
